COMP <GO>
ENOV vs MRK // FREE CASH FLOW YIELD
Enovis Corporation (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ENOV 2
— MRK 8
▲ FREE CASH FLOW YIELD LEADER: MRK
LAST: $19.91 (-12.71%) • MKT CAP: $1.32B
fcf-yield
1.51%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
fcf-yield
3.42%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENOV VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENOV | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.80% | 74.80% | -15.00 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.70% | 20.70% | -53.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 1.51% | 3.42% | -1.91 | MRK | /fcf-yield <GO> |
| Operating Margin | -50.00% | 34.30% | -84.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -52.70% | 28.10% | -80.80 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 6.70% | 1.30% | +5.40 | ENOV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.19 | -4.99 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.3 | 51.7 | +9.60 | ENOV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.32B | $361.02B | -$359.71B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENOV REV | MRK REV | ENOV GROSS % | MRK GROSS % | ENOV FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.25B | $65.01B | 59.8% | 74.8% | $19.9M | $12.36B |
| FY 2024 | $2.11B | $64.17B | 56.0% | 76.3% | -$67.2M | $18.10B |
| FY 2023 | $1.71B | $60.12B | — | — | $135.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENOV // BETA —
MRK // BETA 0.92